GLP-1s and Productivity: Are They Changing the Workplace?

New 2026 research links GLP-1 treatment with less long-term sick leave. Could quieter food noise, better metabolic health and improved wellbeing also be changing the way we work?

We knew GLP-1’s could change waistlines. We knew GLP-1 medications were changing restaurants, supermarkets, alcohol sales and, apparently, the size of dinner plates. But workplace productivity? Now you’ve got my attention.

Many years ago, I worked at Microsoft during a period when my waistline appeared to be growing almost as quickly as Microsoft Corporation. Microsoft was expanding globally. I was expanding locally. There were long days, corporate lunches, dinners, deadlines, travel — and that wonderful office phenomenon where someone puts food in the kitchen and you are apparently legally obliged to eat it.

If GLP-1s had been around then, would I have been more productive? Who knows. But I might have spent considerably less time wondering what was for lunch. And that brings us to a genuinely fascinating new conversation: the Ozempic economy.

GLP-1 users had 17.3% less long-term sick leave

In July 2026, researchers published an NBER working paper examining the labour-market effects of GLP-1 treatment using linked Danish health and employment data. The headline finding was hard to ignore.

The researchers also estimated fiscal benefits equivalent to roughly 1.3 to 1.5 per cent of annual labour income per employed person initiating treatment. Now that should get the attention of HR directors.

But let’s not turn interesting science into Insta-famous wellness science. The same researchers did not find statistically significant or economically meaningful improvements in employment, labour-force participation or income over four years. This is also a working paper, so the sensible interpretation is not “Ozempic makes you 17 per cent more productive”. What we can fairly say is more interesting than that: GLP-1 treatment may be starting to have measurable effects beyond the clinic and into the workplace.

Welcome to the GLP-1 economy

Forbes has already been asking the bigger question, using the term “Ozempic economy” to explore how GLP-1 medications might affect workplace performance, expectations, employee benefits and inequality in access. That conversation is only going to get louder.

But there is another part of this story that particularly interests me as a Nutritional Medicine Practitioner: food noise.

Imagine having a meeting in your head about food, all day

You know the internal conversation. What’s for lunch? Should I eat that biscuit? No. Don’t eat the biscuit. Maybe just half. Who eats half a biscuit? Why did I eat three biscuits? What’s for dinner?

It’s basically a Teams meeting nobody scheduled and nobody knows how to leave. And it can be exhausting.

“Food noise” is increasingly used to describe persistent, intrusive thoughts about food. A 2026 US survey of adults using injectable semaglutide for weight management (the INFORM survey) found a substantial self-reported reduction in food-noise scores after treatment, with the proportion of people agreeing with statements indicating food noise falling markedly.

Important caveat: this was a retrospective survey, not proof that semaglutide directly improves workplace concentration or productivity, and researchers are still working out exactly how to define and measure food noise. But is it reasonable to ask whether removing some of that constant chatter could free up mental bandwidth? Absolutely. It’s a fascinating question, and one I suspect we’ll hear a great deal more about.

Is this really about GLP-1’s or about becoming healthier?

The less glamorous, but probably more important, explanation is simply improved health. If someone’s metabolic health improves and the burden of obesity-related illness falls, perhaps fewer prolonged absences from work shouldn’t surprise us at all.

Which raises a far more useful question for employers than “Can Ozempic make my team work harder?” The better question is: how do we properly support employees who are already, medically, using these medications?

Should companies be investing in GLP-1 support?

Notice I said support. I’m not suggesting Ozempic replace the fruit bowl in the corporate kitchen. GLP-1 medications are prescription medicines. They are not productivity drugs, and nobody should ever feel pressure from an employer to take one.

But organisations already invest heavily in employee wellbeing. If employees are being medically prescribed GLP-1s, that support shouldn’t stop at access to the medication. An injection does not automatically teach somebody how to eat enough protein when appetite disappears, protect muscle, manage nausea or constipation, exercise appropriately, or navigate food noise if it returns.

Giving someone a GLP-1 without helping them navigate those things strikes me as a little like giving them a Microsoft laptop without the operating system. Great piece of equipment. We may have missed something rather important.

The uncomfortable side: access, fairness and “corporate doping”

The workplace discussion also raises some genuinely uncomfortable ethical questions. If access to GLP-1 medications eventually affects health, absence or perceived performance, could we create another divide between people who can access treatment and those who can’t?

I would be deeply uncomfortable with any workplace culture suggesting that taking a medication makes someone more disciplined, ambitious or employable. Obesity treatment is healthcare. It is not corporate doping. And the current evidence certainly does not justify treating GLP-1s as productivity drugs.

Perhaps we’ve been measuring the wrong outcome

For decades, corporate wellness has talked about productivity. I prefer another word: wellbeing.

What happens when somebody has better metabolic health, fewer prolonged periods away from work, less intrusive food noise, more confidence in their physical health, or simply more energy for the rest of their life? Perhaps the interesting question isn’t “Does Ozempic make employees more productive?” It’s: what happens when people become healthier and have more mental and physical capacity available for everything else?

That includes work. But it also includes relationships, parenting, movement, sleep, confidence and simply feeling better. If we’re entering the Ozempic economy, let’s make sure we’re not merely funding the medication. Let’s support the human being taking it.

GLP-1’s and productivity: frequently asked questions

Does Ozempic make you more productive at work? There’s no good evidence that it directly boosts productivity. A 2026 NBER study linked GLP-1 treatment to about 17 per cent less long-term sick leave, but found no meaningful change in employment or income. Better health, not sharper performance, is the likely driver.

What is the “Ozempic economy”? It’s a term (popularised by Forbes) for the wider economic ripple effects of GLP-1 medications — on workplaces, employee benefits, food and retail spending, and questions of fair access.

What is food noise, and do GLP-1s reduce it? Food noise is the persistent, intrusive mental chatter about food. In the 2026 INFORM survey, people on injectable semaglutide reported a substantial drop in it — though whether that translates into better focus at work is still an open research question.

Should employers pay for GLP-1 medications? That’s a policy decision for each organisation. The more useful point is that if a workplace supports access, it should also support the person — with nutrition, muscle preservation, gut health and psychological wellbeing — not just the prescription.

Have you noticed a change?

Have you noticed changes in your energy, concentration, food noise or workday since starting a GLP-1 medication? I’d love to hear what’s shifted for you.

Evidence and further reading

• NBER — The Labor Market Impacts of GLP-1s (working paper w35475, July 2026)

• Advances in Therapy — The INFORM survey on injectable semaglutide and food noise (2026)

• Forbes — “The Ozempic Economy Is Here”

Note: This article is educational and reflects emerging, early-stage research. It is not medical advice, and GLP-1 medications should only be used under the guidance of a qualified health professional.